Sandoz has reached a $275 million settlement with the end-payer plaintiffs' class in the U.S. Generic Drug Antitrust Class Action litigation, resolving claims related to alleged anticompetitive conduct from 2009 to 2019. This agreement, which includes no admission of wrongdoing, is subject to court approval and follows previous settlements with the U.S. Department of Justice and direct purchaser plaintiffs. Additionally, Sandoz has set aside $265 million for outstanding claims from opt-out plaintiffs and state attorneys general.
